Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease.

[1]  L. Klareskog,et al.  Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells , 2008, Annals of the rheumatic diseases.

[2]  M. Gaxiola,et al.  Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. , 2006, The Journal of clinical investigation.

[3]  R. V. Van Uitert,et al.  The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment , 2010, Arthritis research & therapy.

[4]  A. Nicholson,et al.  Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. , 2007, American journal of respiratory and critical care medicine.

[5]  J. Norris,et al.  Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. , 2010, Rheumatic diseases clinics of North America.

[6]  J. Norris,et al.  Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis , 2007, Annals of the rheumatic diseases.

[7]  F. Tubach,et al.  High Levels of Anti-Cyclic Citrullinated Peptide Autoantibodies Are Associated with Co-occurrence of Pulmonary Diseases with Rheumatoid Arthritis , 2011, The Journal of Rheumatology.

[8]  S. Jeong.  Interstitial Lung Diseases in Collagen Vascular Diseases , 2009 .

[9]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[10]  V. Cottin,et al.  The syndrome of combined pulmonary fibrosis and emphysema. , 2009, Chest.

[11]  K. Leslie,et al.  Pulmonary pathology of the rheumatic diseases. , 2007, Seminars in respiratory and critical care medicine.

[12]  S. Teramoto,et al.  A clue to diagnosing connective tissue disease-associated interstitial lung disease. , 2011, Chest.

[13]  S. West,et al.  Connective tissue disease-associated interstitial lung disease: a call for clarification. , 2010, Chest.

[14]  K. Brown,et al.  Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA , 2009, Clinical Rheumatology.

[15]  R. Crapo,et al.  Single-breath carbon monoxide diffusing capacity. , 2001, Clinics in chest medicine.

[16]  M. Malaise,et al.  Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[17]  Hiroshi Watanabe,et al.  Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. , 2008, Clinical biochemistry.

[18]  H. Visser,et al.  A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[19]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[20]  K. Brown.  Rheumatoid lung disease. , 2007, Proceedings of the American Thoracic Society.

[21]  R. Blide,et al.  Pulmonary function testing in the office. , 1969, Maryland state medical journal.

[22]  M. Dougados,et al.  Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review , 2005, Annals of the rheumatic diseases.

[23]  R. Cherniack.  Pulmonary function testing , 1977 .